Alcon Laboratories (Australia)

13 PBAC submissions on file, active 2005–2025. 77% have been recommended.

Drug portfolio

Sorted by PBS spend captured. PBS expenditure is credited to the sponsor with the most recent Recommended decision per drug, so biosimilars and originator brands aren't double-counted.

• Anecortave acetate
  Ophthalmology · Recommended with restriction · 2006—
• Polyethylene glycol 400 with propylene glycol
  Ophthalmology · Recommended · 2025—
• Travoprost with timolol maleate, eye drops
  Ophthalmology · Recommended with restriction · 2007—
• Brinzolamide/brimonidine tartrate
  Ophthalmology · Recommended with restriction · 2015—
• Ciprofloxacin, ear drops
  Other · Recommended with restriction · 2006—
• Hyaluronic acid with polyethylene glycol 400 with propylene glycol with hydroxypropyl guar
  Ophthalmology · Recommended with restriction · 2023—
• Hypromellose
  Ophthalmology · Recommended · 2021other sponsor
• Ocriplasmin
  Ophthalmology · Recommended with restriction · 2019other sponsor
• Propylene glycol
  Ophthalmology · Recommended with restriction · 2024—
• Travoprost with timolol maleate
  Ophthalmology · Not recommended · 2005—

Therapy area mix

Activity by year

2005 (1) · 2006 (4) · 2007 (1) · 2014 (1) · 2015 (1) · 2018 (1) · 2021 (1) · 2023 (1) · 2024 (1) · 2025 (1)

Rejection patterns

Across 3 Not recommended decisions on file.

• 1×Uncertain clinical benefit (VMA resolution did not reliably predict avoidance of vitrectomy
• 1×no difference in best corrected visual acuity at 28 days or 6 months
• 1×minimal clinically important difference exceeded)
• 1×subgroup analyses not robust and overly relied upon
• 1×supply chain and cold storage logistical concerns